Payday? Here's why the CSL share price is sliding this morning…

The CSL share price is underperforming today, but for good reason…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The ASX 200 has had a rough start to the week so far on Monday
  • But CSL shares are faring even worse
  • CSL shares are trading ex-dividend today

The S&P/ASX 200 Index (ASX: XJO) has had a bit of a topsy-turvy start to the trading week so far this Monday. At the time of writing, the ASX 200 is down by 0.64% after spending time in both positive and negative territory already today. But let's check out what the CSL Limited (ASX: CSL) share price is up to.

At the time of writing, CSL shares are trading for $254.12 each. That's down around 1.62% so far.

So is there any good reason why CSL shares might be trailing the broader market so decisively today?

Well, as it happens, there is.

Today is a big day on the CSL shareholder calendar. It is the day this ASX 200 healthcare company trades ex-dividend for its upcoming interim payment. Last month, CSL delivered its half-year earnings report. Along wth a mixed-bag of results, this naturally included details about CSL's next dividend payment.

This upcoming dividend will be worth US$1.04 per share for investors when it is paid out on 6 April. The final value in Australian dollars is yet to be determined. But it works out to be approximately $1.41 on today's exchange rates. The dividend will come unfranked. At US$1.04 per share, it is also flat on last year's interim dividend.

So the fact that this dividend has now gone 'ex' is probably at least partially why the CSL share price is showing weakness today. When a company trades ex-dividend, the value of the dividend payment in question leaves the company's share price. That's because, from today, no new CSL shareholders will be entitled to receive the company's upcoming payment. This means the shares are effectively worth less today than they were on Friday.

a woman looks down at her phone with a look of concern on her face and her hand held to her chin while she seriously digests the news she is receiving.

Image source: Getty Images

CSL share price snapshot

Like many ASX 200 shares, CSL hasn't had the easiest ride in 2022 so far. This healthcare giant has lost more than 14% year to date. However, the company is still up around 3.5% over the past 12 months, and up more than 102% over the past five years.

At the current CSL share price, the company has a market capitalisation of $124.7 billion, with a dividend yield of 1.14%.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »